- How many patients were treated in the past three months for gastric cancer (any stage) with:
CAPOX (Capecitabine with Oxaliplatin)
FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin)
Lonsurf (Trifluridine - tipiracil)
Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and
Fluoropyrimidine (5-Fluorouracil or Capecitabine)
Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and
Fluoropyrimidine (5-Fluorouracil or Capecitabine)
Any other systemic anti-cancer therapy
Palliative care only
Zolbetuximab (Vyloy)
- How many patients were treated in the past 3 months for cancer of the gastro-oesophageal
junction (any stage) with:
CAPOX (Capecitabine with Oxaliplatin)
FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin)
Lonsurf (Trifluridine - tipiracil)
Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and
Fluoropyrimidine (5-Fluorouracil or Capecitabine)
Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and
Fluoropyrimidine (5-Fluorouracil or Capecitabine)
Zolbetuximab (Vyloy)
Any other systemic anti-cancer therapy
Any other systemic anti-cancer therapy
Freedom of Information (Scotland) Act 2002
Environmental Information (Scotland) Regulations 2004
- How many patients were treated in the last 3 months with any systemic anti-cancer therapiesfor Gastric cancer or cancer of the Gastro-Oesophageal Junction?
Given the small numbers of patients involved; the specific and sensitive nature of the health conditions referred to; the size of Shetland’s population; the specific treatments; and the short timeframe, NHS Shetland considers that providing any answers to questions 1, 2 or 3 carries a high risk of identifying individuals. As such and in accordance with FOISA s 16(1), NHS Shetland confirms that it holds the information requested but that it is exempt from disclosure under FOISA s 38(1)(b) as read with s 38 (2A) as the information constitutes personal data and disclosure would breach the confidentiality of the data subjects.
